FirstWave Bio to Initiate Phase 2a/2b Study of FW-1022, a Proprietary Form of Niclosamide, to Treat COVID-19

Proprietary formulation of approved antiviral medicine targets viral “reservoir” in the gut believed responsible for prolonged…